AIFA Agenzia Italiana del Farmaco
Web activation and publication of monitoring cards – Registro Imfinzi (ES SCLC)
Users of the Drug Registries subject to Monitoring are informed that, following the publication of the AIFA Determine in the OJ no. 259 of , starting from the it is possible to use, under the NHS reimbursement scheme, IMFINZI (durvalumab) for the following therapeutic indication:
IMFINZI in combination with etoposide and carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extended small cell lung cancer (ES-SCLC).
Please note that the prescriptions relating only to the indication reimbursed by the National Health Service, through the aforementioned publication, must be carried out in accordance with the criteria of eligibility and prescriptive appropriateness reported in the clinical card, downloadable from the list of “Active Registers and PT”, accessible from the “Related Links” box.
Finally, it is specified that, starting from , the register in question is available on the web platform; therefore the regional referents are invited to proceed with the authorization of authorized health centers, accessing the system.
Monitoring Registers Office
Published on:
Access to the site is restricted and reserved for healthcare professionals
You have reached the maximum number of visits
Source – https://www.univadis.it/viewarticle/attivazione-web-e-pubblicazione-schede-di-monitoraggio—registro-imfinzi-es-sclc